[1] Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.
[2] Qi C, Mao X, Zhang Z, et al. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017;2017:8637138.
[3] Wang G, Ouyang J, Li S, et al. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. J Transl Med. 2019;17:264.
[4] Zhou T, Sun L, Yang S, et al. 20(S)-Ginsenoside Rg3 Protects Kidney from Diabetic Kidney Disease via Renal Inflammation Depression in Diabetic Rats. J Diabetes Res. 2020;2020:7152176.
[5] Liu S, Ye L, Tao J, Ge C, et al. Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats. Pharm Biol. 2017;56:1-11.
[6] Lai X, Tong D, Ai X, et al. Amelioration of diabetic nephropathy in db/db mice treated with tibetan medicine formula Siwei Jianghuang Decoction Powder extract. Sci Rep. 2018;8:16707.
[7] Xu X, Li QJ, Xia S, Wang MM, Ji W. Tripterygium Glycosides for Treating Late-onset Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Altern Ther Health Med. 2016;22:32-39.
[8] Ho LJ, Chang WL, Chen A, et al. Differential immunomodulatory effects by Tripterygium wilfordii Hook f-derived refined extract PG27 and its purified component PG490 (triptolide) in human peripheral blood T cells: potential therapeutics for arthritis and possible mechanisms explaining in part Chinese herbal theory "Junn-Chenn-Zuou-SS". J Transl Med. 2013;11:294.
[9] Ding Y, Zhang X, Ren X, et al. Traditional Chinese medicine versus regular therapy in Henoch-Schönlein purpura nephritis in children: study protocol for a randomized controlled trial. Trials. 2019;20:538.
[10] Wu W, Yang JJ, Yang HM, et al. Multi-glycoside of Tripterygium wilfordii Hook. f. attenuates glomerulosclerosis in a rat model of diabetic nephropathy by exerting anti-microinflammatory effects without affecting hyperglycemia. Int J Mol Med. 2017;40:721-730.
[11] Ren D, Zuo C, Xu G. Clinical efficacy and safety of Tripterygium wilfordii Hook in the treatment of diabetic kidney disease stage IV: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e14604.
[12] Zheng XY. Guidelines for Clinical Research of New Chinese Medicine Drugs (trial). Beijing: China Medical Science Press; 2002. 156.
[13] Cai XP. ARB combined with Tripterygium glycosides in the treatment ofdiabetic nephropathy. J Clin Med Pract. 2012;16:112–4.
[14] Wang W. Different Doses of Tripterygium Glycosides in the Treatment of Diabetic Nephropathy: Effects on Blood Lipids. Kidney Blood Press Res. 2018;43:931-937.
[15] Nie CY, Chen LM, Chang BC, et al. The effect of tripterygium wilfordii on proteinuria in patients with diabetic nephropathy. Chinese Journal of Practical Internal Medicine. 2009;29:517-519.
[16] Chen H, Zhuang LP, Liu JF, et al. Effect of Irbesartan and Triptolide com bination on the level of urine protein in patients with diabetic nephropathy at high altitude area. Clinical Medicine of China. 2012,11:1149-1151.
[17] Song HX, Gong J, Chen W, et al. Effect of Triptol ide on Urinary Monocyte Chemottractant Protein-1 in Patients with Diabetic Nephropathy. Chinese Journal of Integrated Traditional and Western Medicine. 2005;5:416-418.
[18] Feng B, Ye ZL, Yang X, et al. Effect of triptolide on microinflammation in the patients with diabetic nephropathy. J Clin Nephrol, 2009,9(2):82-84.
[19] Guo YQ, Zuo YH. Clinical analysis of effect of Tripterysium glucosides in treatment of diabetic nephropathy. J Clin Nephrol. 2007;7:198-199.
[20] Fan HY, Shi YJ. Effect of Triptolide on Transforming Growth Factor -β in Diabetic Nephropathy Cases. Chinese Journal of Integrated Traditional and Western Nephrology. 2005;7:395-397.
[21] Tu CF, Wang LJ, Gu LJ, et al. Effect of tripterygium wilfordii polyglycoside combined telmisartan on renal function and hemorheology in patients with diabetic nephropathy. Chinese Journal of General Practice. 2017;15:1527-1528+1595.
[22] Jiang X. Clinical observation of tripterygium glycosides combined with telmisartan in treatment 391 of diabetic nephropathy. Drugs & Clinic. 2015;30:987-90. 392
[23] Wu YP, Shi NC. Clinical observation on the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy stage Ⅳ. Chinese Remedies & Clinics. 2018;18:753-754.
[24] Xu GB, Chen DJ, Chen WZ. Effect of Tripterygium Wilfordii Polyglycoside on Inflammatory FactorLevel in Patients with Diabetic Nephropathy, Chinese Archives of Traditional Chinese Medicine. 2017;35:2206-2208.
[25] Zhang HC. A clincial study of tripterygium glycosides tablets adjuvanttreatment of diabetic nephropathy during IV period. China Pharmaceuts. 2015;24:248–9.
[26] Su HJ, Qian Y, Li HS. Efficacy of tripterygium glycosides on proteinuria patients with diabetic nephropathy. Medical Journal of Wuhan University. 2013;34:296-298.
[27] Ge YC, Xie HL, Li SJ. Effect of tripterygium wilfordli in patients with diabetic nephropathy:a prospective randomized control clinical trial. J Nephrol Dialy Transplant. 2010;19:501-507+533.
[28] Wang ML, Zhang C. Clinical observation of Valsartan combined with Tripterygium wilfordii in the treatment of proteinuria in type 2 diabeticnephropathy. Chin J Clin Rational Drug Use. 2012;5:84–5.
[29] Jiang AL, Chu XY, Wang HT. Clinical observation on the effect of low-dose tripterygium glycosides on proteinuria in diabetic nephropathy. Chin J Integr Traditional West Nephrol. 2014;15:444-445.
[30] Tang ZH, Luo DW, Yuan WJ. A randomized controlled study of tripterygium glycosides polyglycoside in the treatment of diabetic nephropathy with moderate non-proliferative retinopathy. Chin J Integr Traditional West Nephrol. 2017;18:332-334.
[31] Zhao RY, Tang BS, Shi XL, et al. Clinical observation on 46 cases ofdiabetic nephropathy treated with Tripterygium wilfordii and Valsartan. Chin J Integr Traditional West Nephrol. 2011;12:811–3.
[32] Yin ZH, Xia Li. Clinical observation of tripterygium wilfordii polyglycoside on proteinuria in diabetic nephropathy. Lishizhen Medicine and Materia Medica Research. 2014;25:1676.
[33] Zheng XP. Clinical observation of tripterygium wilfordii on diabetic nephropathy. Journal of Clinical and Experimental Medicine. 2009;8:134-135.
[34] Ma RX, Zhao N, Zhang W. The effects and m echanism of tripterygium wilfordii Hook F com bination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients. Chin J Intern Med. 2013;52:469-73.
[35] Chang X, Li L, Wang B, et al. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. J Formos Med Assoc. 2020;119:685-692.
[36] Ma RX, Xu Y, Jiang W, et al. Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease. Biotechnol Biotechnol Equip. 2015;29:139-146.
[37] Gao SP. A randomized controlled study of Tripterygium wilfordii polyglycoside in the treatment of diabetic nephropathy. Hainan Medical Journal. 2012;23:31-32.
[38] Zheng YH. Tripterygium wilfordii clinical research for the treatment of diabetic nephropathy stage IV[Master]: Guangzhou University of Chinese Medicine; 2014.
[39] Ringholm L, Damm JA, Vestgaard M, et al. Mathiesen ER. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016;16(2):12.
[40] Yamahara K, Yasuda M, Kume S, Koya D, Maegawa H, Uzu T. The role of autophagy in the pathogenesis of diabetic nephropathy. J Diabetes Res. 2013;2013:193757.
[41] Hong Y, Gui Z, Cai X, et al. Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis. Open Med (Wars). 2016 Dec 30;11(1):611-617.
[42] Abdelhafiz AH, Nahas ME, de Oliveira JM. Management of diabetic nephropathy in older patients: a need for flexible guidelines. Postgrad Med. 2014 Jul;126(4):171-7.
[43] Huang YR, Wan YG, Sun W, et al. Effects and mechanisms of multi-glycoside of Tripterygium wilfordii improving glomerular inflammatory injury by regulating p38MAPK signaling activation in diabetic nephropathy rats. Zhongguo Zhong Yao Za Zhi. 2014;39(21):4102-9. Chinese.
[44] Wang S, Li R, He S,et al. Tripterygium wilfordii Glycosides Upregulate the New Anti-Inflammatory Cytokine IL-37 through ERK1/2 and p38 MAPK Signal Pathways. Evid Based Complement Alternat Med. 2017;2017:9148523.
[45] Fang JY, Yang Y, Zhang Z, Jiang SM, Yu TY, Li WG. Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy. Chronic Dis Transl Med. 2020 Feb 10;6(1):18-26.
[46] Wu X, Huang Y, Zhang Y, et al. Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis. Biosci Rep. 2020 Nov 27;40(11):BSR20202391.